How Global Trends Are Driving Patient-Centricity in Parenteral Products.
After only one year our location in Austria has been modified to the high Vetter quality standards as it prepares to begin manufacturing.
The key to successful development and guiding a drug to approval is early planning.
Fast, safe and efficient: the new Vetter ID determination of oligonucleotides.
92 percent of our colleagues in Chicago named Vetter a “Great Place to Work” company!
In this article Senior Vice President Kai Vogt talks about the opportunities of digital transformation at Vetter.
Renewed award confirms continuity and the approach to sustainability.
Rentschler Biopharma and Vetter announced today that their strategic collaboration has taken key steps forward.
Interview with Oskar Gold, SVP Asia Pacific and Global Emerging Markets
Vetter expands its activities in Asia. The new office, located in the heart of Shanghai's Central Business District.
Winning five core categories reaffirms Vetter as a trusted solution provider.
Around four million people in Germany live with one of the approximately 6,000 various rare diseases.